Collegium Pharmaceutical (NASDAQ:COLL) Trading 2.8% Higher – Time to Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares shot up 2.8% during mid-day trading on Wednesday . The company traded as high as $30.00 and last traded at $29.97. 25,883 shares were traded during trading, a decline of 93% from the average session volume of 368,973 shares. The stock had previously closed at $29.14.

Analysts Set New Price Targets

A number of research analysts have commented on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Piper Sandler reiterated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Price Performance

The firm has a market cap of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a 50 day moving average price of $30.57 and a 200 day moving average price of $34.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Pacer Advisors Inc. boosted its position in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after buying an additional 821,541 shares in the last quarter. Rubric Capital Management LP lifted its position in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after acquiring an additional 499,473 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares in the last quarter. Emerald Advisers LLC raised its holdings in Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.